AIFA: molecules with a published decision record
152 molecules on this site carry at least one AIFA decision. Each page compares that decision with every other agency that assessed the same molecule.
| Molecule | Decisions | Agencies | Class |
|---|---|---|---|
| pembrolizumab | 371 | 15 | Antineoplastics |
| nivolumab | 264 | 15 | Antineoplastics |
| adalimumab | 133 | 11 | Immunosuppressants |
| atezolizumab | 120 | 14 | Antineoplastics |
| dupilumab | 116 | 15 | Other dermatologicals |
| daratumumab | 115 | 15 | Antineoplastics |
| olaparib | 114 | 15 | Antineoplastics |
| durvalumab | 108 | 15 | Antineoplastics |
| ibrutinib | 108 | 15 | Antineoplastics |
| rituximab | 94 | 9 | Antineoplastics |
| upadacitinib | 93 | 16 | Immunosuppressants |
| ivacaftor | 79 | 12 | Other respiratory |
| budesonide | 76 | 12 | Antidiarrheals / intestinal anti-inflammatories |
| tocilizumab | 76 | 12 | Immunosuppressants |
| lenalidomide | 68 | 13 | Immunosuppressants |
| osimertinib | 65 | 14 | Antineoplastics |
| blinatumomab | 64 | 14 | Antineoplastics |
| dapagliflozin | 64 | 12 | Diabetes |
| empagliflozin | 64 | 13 | Diabetes |
| trastuzumab deruxtecan | 64 | 14 | Antineoplastics |
| venetoclax | 61 | 14 | Antineoplastics |
| mepolizumab | 59 | 15 | Obstructive airway diseases |
| ipilimumab | 58 | 14 | Antineoplastics |
| zanubrutinib | 58 | 16 | Antineoplastics |
| cabozantinib | 56 | 15 | Antineoplastics |
| cemiplimab | 55 | 13 | Antineoplastics |
| rivaroxaban | 55 | 11 | Antithrombotics |
| brentuximab vedotin | 54 | 12 | Antineoplastics |
| ravulizumab | 54 | 15 | Immunosuppressants |
| selpercatinib | 53 | 13 | Antineoplastics |
| acalabrutinib | 52 | 14 | Antineoplastics |
| ribociclib | 50 | 14 | Antineoplastics |
| lenvatinib | 49 | 14 | Antineoplastics |
| nintedanib | 49 | 15 | Antineoplastics |
| baricitinib | 48 | 14 | Immunosuppressants |
| abemaciclib | 47 | 15 | Antineoplastics |
| amivantamab | 47 | 13 | Antineoplastics |
| avelumab | 42 | 13 | Antineoplastics |
| niraparib | 42 | 15 | Antineoplastics |
| dostarlimab | 39 | 14 | Antineoplastics |
| eculizumab | 39 | 11 | Immunosuppressants |
| dabrafenib | 38 | 14 | Antineoplastics |
| isatuximab | 38 | 12 | Antineoplastics |
| alectinib | 37 | 15 | Antineoplastics |
| alirocumab | 37 | 13 | Lipid modifying agents |
| obinutuzumab | 37 | 12 | Antineoplastics |
| tisagenlecleucel | 37 | 12 | Antineoplastics |
| cannabidiol | 35 | 12 | Antiepileptics |
| emicizumab | 35 | 12 | Antihemorrhagics |
| axicabtagene ciloleucel | 34 | 12 | Antineoplastics |
| burosumab | 34 | 13 | Bone diseases |
| esketamine | 33 | 13 | Psychoanaleptics |
| pegcetacoplan | 33 | 16 | Ophthalmologicals |
| carfilzomib | 32 | 11 | Antineoplastics |
| pertuzumab | 32 | 13 | Antineoplastics |
| canakinumab | 31 | 10 | Immunosuppressants |
| sacituzumab govitecan | 31 | 15 | Antineoplastics |
| entrectinib | 30 | 13 | Antineoplastics |
| fingolimod | 30 | 12 | Immunosuppressants |
| regorafenib | 30 | 12 | Antineoplastics |
| larotrectinib | 29 | 14 | Antineoplastics |
| palbociclib | 29 | 13 | Antineoplastics |
| sofosbuvir | 29 | 11 | Antivirals |
| encorafenib | 28 | 12 | Antineoplastics |
| letermovir | 28 | 14 | Antivirals |
| ocrelizumab | 28 | 12 | Immunosuppressants |
| tafamidis | 28 | 16 | Other nervous system |
| abiraterone | 27 | 10 | Endocrine therapy |
| enfortumab vedotin | 27 | 13 | Antineoplastics |
| lisocabtagene maraleucel | 27 | 11 | Antineoplastics |
| vutrisiran | 27 | 15 | Other nervous system |
| cladribine | 26 | 12 | Immunosuppressants |
| fenfluramine | 26 | 14 | Antiepileptics |
| glofitamab | 26 | 13 | Antineoplastics |
| azacitidine | 25 | 11 | Antineoplastics |
| brigatinib | 25 | 14 | Antineoplastics |
| cabotegravir | 25 | 10 | Antivirals |
| talazoparib | 25 | 13 | Antineoplastics |
| iptacopan | 24 | 12 | Immunosuppressants |
| odevixibat | 24 | 13 | Bile and liver therapy |
| tirzepatide | 24 | 12 | Diabetes |
| epcoritamab | 23 | 14 | Antineoplastics |
| lanadelumab | 23 | 15 | Other hematological agents |
| polatuzumab vedotin | 23 | 13 | Antineoplastics |
| setmelanotide | 23 | 10 | Antiobesity preparations |
| asciminib | 22 | 15 | Antineoplastics |
| luspatercept | 22 | 9 | Antianemics |
| midostaurin | 22 | 11 | Antineoplastics |
| selinexor | 22 | 11 | Antineoplastics |
| belantamab mafodotin | 21 | 10 | Antineoplastics |
| erenumab | 21 | 13 | Analgesics |
| galcanezumab | 21 | 13 | Analgesics |
| fremanezumab | 20 | 13 | Analgesics |
| pirtobrutinib | 20 | 14 | Antineoplastics |
| trastuzumab emtansine | 20 | 12 | Antineoplastics |
| atogepant | 19 | 13 | Analgesics |
| exagamglogene autotemcel | 19 | 9 | Other hematological agents |
| rimegepant | 19 | 10 | Analgesics |
| tucatinib | 19 | 13 | Antineoplastics |
| belzutifan | 18 | 13 | Antineoplastics |